|
Synonyms: compound 7 [US20210238168A1] | Povofortay®
Compound class:
Synthetic organic
Comment: The chemical structure for povorcitinib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a Janus kinase inhibitor and anti-inflammatory agent. It is one of the examples claimed in Incyte's JAK inhibitor patent US20210238168A1 [1], which indicates selectivity for JAK1. At that time information on Incyte's pipeline page suggested that povorcitinib may be the INN for their oral JAK1 inhibitor clinical lead INCB54707, and this INN-to-code name was formally confirmed in 2026 [3].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Povorcitinib is a clinical candidate for the treatment of hidradenitis suppurativa, chronic spontaneous urticaria and other inflammatory conditions |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05936567 | Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria | Phase 2 Interventional | Incyte Corporation | ||
| NCT05620823 | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | Phase 3 Interventional | Incyte Corporation | The STOP-HS1 study | 2 |
| NCT05620836 | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) | Phase 3 Interventional | Incyte Corporation | The STOP-HS2 study | 2 |